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Background: Perturbation of endothelial function in people with cystic fibrosis (CF) has
been reported, which may be associated with endothelial cell expression of the cystic
fibrosis transmembrane conductance regulator (CFTR). Previous reports indicate that
CFTR activity upregulates endothelial barrier function, endothelial nitric oxide synthase
(eNOS) expression and NO release, while limiting interleukin-8 (IL-8) release, in human
umbilical vein endothelial cells (HUVECs) in cell culture. In view of reported microvascular
dysfunction in people with CF we investigated the role of CFTR expression and activity
in the regulation of oxidative stress, cell signaling and inflammation in human lung
microvascular endothelial cells (HLMVECs) in cell culture.
Methods: HLMVECs were cultured in the absence and presence of the CFTR
inhibitor GlyH-101 and CFTR siRNA. CFTR expression was analyzed using qRT-PCR,
immunocytochemistry (IHC) and western blot, and function by membrane potential
assay. IL-8 expression was analyzed using qRT-PCR and ELISA. Nrf2 expression, and
NF-κB and AP-1 activation were determined using IHC and western blot. The role of the
epidermal growth factor receptor (EGFR) in CFTR signaling was investigated using the
EGFR tyrosine kinase inhibitor AG1478. Oxidative stress was measured as intracellular
ROS and hydrogen peroxide (H2O2) concentration. VEGF and SOD-2 were measured
in culture supernatants by ELISA.
Results: HLMVECs express low levels of CFTR that increase following inhibition of
CFTR activity. Inhibition of CFTR, significantly increased intracellular ROS and H2O2
levels over 30 min and significantly decreased Nrf2 expression by 70% while increasing
SOD-2 expression over 24 h. CFTR siRNA significantly increased constitutive expression
of IL-8 by HLMVECs. CFTR inhibition activated the AP-1 pathway and increased IL-8
Frontiers in Physiology | www.frontiersin.org 1 July 2020 | Volume 11 | Article 879
fphys-11-00879 July 27, 2020 Time: 18:29 # 2
Khalaf et al. Endothelial CFTR Function
expression, without effect on NF-κB activity. Conversely, TNF-α activated the NF-κB
pathway and increased IL-8 expression. The effects of TNF-α and GlyH-101 on IL-8
expression were additive and inhibited by AG1478. Inhibition of both CFTR and EGFR
in HLMVECs significantly increased VEGF expression. The antioxidant N-acetyl cysteine
significantly reduced ROS production and the increase in IL-8 and VEGF expression
following CFTR inhibition.
Conclusion: Functional endothelial CFTR limits oxidative stress and contributes to
the normal anti-inflammatory state of HLMVECs. Therapeutic strategies to restore
endothelial CFTR function in CF are warranted.
Keywords: endothelium, CFTR, cystic fibrosis, inflammation, oxidative stress, cell signaling
INTRODUCTION
Cystic fibrosis (CF) lung disease is associated with neutrophilic
airway inflammation, bronchiectasis, respiratory failure, and
early mortality (Nichols and Chmiel, 2015). Defective or deficient
expression of the cystic fibrosis transmembrane conductance
regulator (CFTR) protein, an anion channel conducting mainly
chloride and bicarbonate ions in airway epithelial cells (Saint-
Criq and Gray, 2017), leads to dehydration of airway secretions
with failure of mucociliary clearance and mucus plugging.
In the early stages of CF lung disease this may lead to
sterile inflammation (Zhou-Suckow et al., 2017), but inevitably
the airways become chronically infected leading to further
interleukin-8 (IL-8) driven neutrophilic inflammation (Nichols
and Chmiel, 2015). In more severe disease, increased expression
of vascular endothelial growth factor (VEGF) and associated
peribronchial vascularity contributes to the immune and
inflammatory responses in the CF airway, as well as the risk of
hemoptysis (Martin et al., 2013).
A number of studies have indicated macro- and microvascular
endothelial perturbation in people with CF (Romano et al., 2001;
Solic et al., 2005; Poore et al., 2013; Rodriguez-Miguelez et al.,
2016; Vizzardi et al., 2019) that may be associated with defective
endothelial CFTR function (Noe et al., 2009; Brown et al., 2014;
Peters et al., 2015; Totani et al., 2017). Increased circulating levels
of von Willebrand factor (vWF) and tissue plasminogen activator
(tPA), indicative of endothelial damage and altered hemostasis
(Romano et al., 2001), and reduced flow-mediated dilation of the
brachial artery, which was associated with more severe airway
disease and symptomatic of reduced NO availability (Poore
et al., 2013), were reported in CF. Hydrogen peroxide (H2O2)-
induced oxidative stress and apoptosis required functional CFTR
in human lung microvascular cells (HLMVEC), effects that
were reversed by the CFTR inhibitor CFTRinh-172 (Noe et al.,
2009). Reduced endothelial apoptosis in the vasculature of the
CF lung has previously been reported which may be associated
with reduced endothelial ceramide concentration (Noe et al.,
2009). Endothelial CFTR plays an important role in maintaining
hydration of the endothelial glycocalyx (Peters et al., 2015), the
endothelial barrier function (Brown et al., 2014; Totani et al.,
2017) and the availability of NO, while limiting IL-8 release
(Totani et al., 2017).
Thus, together with reports of endothelial expression of CFTR
in human umbilical vein endothelial cells (HUVEC) (Tousson
et al., 1998; Totani et al., 2017), HLMVEC (Tousson et al.,
1998), and human pulmonary artery endothelial cells (HPAEC)
(Plebani et al., 2017; Totani et al., 2017), there is a growing
body of evidence for expression and function of CFTR in
the endothelium.
Previous studies have shown that functional CFTR at the
epithelial cell surface is critical for limiting NF-κB mediated
cell signaling leading to IL-8 expression both at baseline and
following activation with pro-inflammatory cytokines IL-1 and
TNF-α (Perez et al., 2007; Vij et al., 2009), for inhibiting
epidermal growth factor receptor (EGFR)-mediated IL-8 (Kim
et al., 2013) and VEGF synthesis (Martin et al., 2013) and
for Nrf-2-mediated adaptive responses to oxidative stress
(Chen et al., 2008).
The present study focuses on the pulmonary microvasculature
and investigates the expression and function of CFTR as a
regulator of oxidative stress, expression of the key transcriptional
regulator of antioxidant defenses nuclear factor erythroid 2
[NF-E2]-related factor 2 (Nrf2), expression of pro-angiogenic
VEGF and of the neutrophil chemoattractant IL-8, and
reactive oxygen species (ROS)-mediated inflammatory cell
signaling in HLMVECs grown on the basement membrane
component, collagen IV.
The overall aim is to identify a role for dysfunctional
endothelial CFTR in systemic inflammation and oxidative stress
and, importantly, new therapeutic targets to reduce systemic
inflammation and oxidative stress in people with CF.
MATERIALS AND METHODS
Materials
All reagents were from Merck unless indicated otherwise.
Cell Culture
Human lung microvascular endothelial cells (HLMVECs)
from non-smoking donors (Lonza Biologics) were maintained
in complete EGM-2MV medium (EBM-2MV basal medium
supplemented with 5% FBS, 0.04% hydrocortisone, 0.4% hFGF,
0.1% VEGF, 0.1% IGF-1, 0.1% ascorbic acid, 0.1% hEGF and 0.1%
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GA-100 (Lonza Biologics) and used at passage 5–8. The growth
medium was changed 1 day after seeding and then every other
day to 90% confluence. Cells were passaged using trypsin-EDTA
to detach them, neutralized with warmed FBS and pelleted by
centrifugation. The cell pellet was re-suspended in full growth
medium (FGM) and seeded in multi-well plates (25 × 104/6-
well plate, 5× 104/24-well plate) coated with human collagen IV
(0.1 mg/ml) and allowed to adhere overnight before treatment
at the indicated times with the CFTR inhibitor GlyH-101 [5,
10, 20 µM (Friard et al., 2017)], dimethyl sulfoxide (DMSO,
0.1%) as vehicle control or TNF-α [10 ng/ml (Chen et al., 2008),
Peprotech] for up to 24 h, which was established by cell viability
testing in the presence of GlyH-101, as described below.
The specificity of GlyH-101 as a CFTR inhibitor
was confirmed using inhibitors of other chloride ion
channels. DCPIB (4-(2-butyl-6,7-dichlor-2-cyclopentyl-
indan-1-on-5-yl) oxybutyric acid) (Tocris), a potent (IC50
4.8 µM) and specific Volume-Regulated Anion Channel
(VRAC) inhibitor was used at 20 µM (Friard et al.,
2017), and Ani9 (2-(4-chloro-2-methylphenoxy)-N-[(2-
methoxyphenyl)methylideneamino]-acetamide), a potent (IC50
77 nM) and specific inhibitor of the calcium-activated chloride
ion channel Transmembrane Member 16A (TMEM16A), also
known as Anoctamin-1 (Ano-1), that lacks inhibitory activity
against CFTR and VRAC (Seo et al., 2016), was used at 10 µM in
HLMVEC cultures. HLMVECs were cultured in 5% CO2 at 37◦C
and used until passage 8.
In separate experiments, HLMVECs were treated with
N-acetyl cysteine [NAC, 5 or 10 mM (Chen et al., 2008), as
indicated] and the EGFR inhibitor AG-1478 [10 µM (Kim et al.,
2013)] for 3 h, followed by incubation with GlyH-101 (20 µM)
alone, and with TNF-α (10 ng/ml) for 16 and 24 h in FGM.
Human embryonic kidney cells (HEK-293) which do not
express CFTR (Friard et al., 2017) and human bronchial epithelial
cells (the human bronchial epithelial cell line 16HBE14o-)
which do express CFTR (Cozens et al., 1994) were used
as negative and positive controls, respectively. HEK-293 and
16HBE cells were cultured as described above in DMEM or
MEM media, respectively, supplemented with 10% FBS, 1%
penicillin-streptomycin, 1% L-glutamine. Cells were maintained
until passage 30.
MTT Assay for Cell Viability
Human lung microvascular endothelial cells were seeded at a
density of 1 × 104 cells/well/100 µl of FGM in collagen-coated
96 well plates and left to adhere overnight at 37◦C and 5%
CO2. Next day the cells were treated with GlyH-101 and DMSO
(0.1%) as vehicle control in FGM for 16, 24, and 48 h. In order
to eliminate the effect of ascorbic acid in FGM on MTT color
changes, the medium were replaced with 100 µl phenol red
free medium (MEM) containing 0.3% of FBS per well. MTT 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (to
a final concentration of 0.5 mg/ml) added to cells for 4 h at
37◦C and 5% CO2 was reduced by cellular metabolic activity to
insoluble formazan, which was solubilized with 100 µl 10% SDS
in 0.01 M HCl overnight, and the absorbance read at 570 nm
using a Spectramax i3x plate reader (Molecular Devices).
CFTR Activity Assay
Cystic fibrosis transmembrane conductance regulator activity
was measured in HLMVECs, 16HBE and HEK-293 cells using
the FLIPR Blue membrane potential assay (Molecular Devices),
according to the manufacturer’s instructions, and as described by
Maitra et al. (2013). Cells were seeded at 8× 103 cells per well and
cultured overnight in collagen IV-coated optical-bottom black
96-well plates in 100 µl FGM. FLIPR Blue (100 µl) was directly
added to the wells for 45 min at 37◦C in FGM. Agonists, forskolin
(100 µM)/IBMX (1000 µM), concentrations that significantly
increase endothelial intracellular cAMP (Hopkins and Gorman,
1981; Sayner et al., 2004), were applied for 2 min and fluorescence
measured with excitation 530 nm and emission 565 nm, using the
Spectramax R© i3x fluorescent plate reader (Molecular Devices).
GlyH-101 (20 µM) or DMSO (0.1%) control were applied
15 min before the agonists. Changes in membrane polarization
are reported as changes in relative fluorescence units (1RFU).
CFTR activity was detected as membrane depolarization at
baseline, and in response to IBMX plus forskolin leading to
increased uptake and fluorescence of intracellular FLIPR Blue,
that could be inhibited by GlyH-101 (Maitra et al., 2013).
Experimental conditions were tested in quadruplicate in each of
three independent experiments.
Preparation of Cell Lysates for CFTR and Nrf2 Protein
Assessment by Western Blot
Cells were lysed directly with 35 µl/well for 24-well (Nrf2)
and 75 µl/well for 6-well (CFTR) plates of 1X sample buffer
[7.5% (v/v) glycerol, 50 mM Tris-Base, 2% (w/v) sodium
dodecyl sulfate (SDS), 100 mM DL-dithiothreitol (DTT), 0.01%
(w/v) bromophenol blue, 2 mM MgCl2, 0.05% (v/v) benzonase
nuclease, 2x protease inhibitor cocktail I], on ice for 10 min.
Finally 1µl of 0.25 M EDTA was added to each lysate and samples
heated in a water bath at 50◦C for 20 min.
Preparation of Cell Lysates for Phospho-c-Jun
Protein Assessment by Western Blot
Human lung microvascular endothelial cells in 6-well plates
were treated with DMSO (0.1%), GlyH-101 (20 µM) or TNF-
α (10 ng/ml) for 30 min and the cells lysed in 100 µl/well
lysis buffer [125 mM NaCl, 1 mM MgCl2, 20 mM Tris–
HCl, 1% Triton X-100, Complete protease inhibitor cocktail
(Roche) and phosphatase inhibitor (PhosSTOP, Roche)] at 4◦C
for 30 min. The cell lysates were centrifuged at 24000 RCF,
at 4◦C for 30 min and stored at −80◦C. Cell lysates (30 µl)
were mixed with 10 µl 4X sample loading buffer (30% v/v
glycerol, 200 mM Tris–HCl pH 6.8, 8% w/v SDS, 400 mM
DTT, 0.04% w/v bromophenol blue), and placed in a water bath
(95◦C) for 4 min.
Gel Electrophoresis and Western Blotting
Samples (35 µl) were loaded onto 7.5% (CFTR) or 10%
(Nrf2, p-c-Jun) SDS-PAGE gels, with 5 µl of a molecular
weight ladder with pre-stained proteins in the molecular size
range 8–220 kDa (Sigma) or 10–250 kDa (Bio-Rad) loaded
on each gel, and resolved proteins transferred using a Trans-
Blot semi-dry transfer cell (Bio-Rad, United Kingdom) to
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0.45 µm nitrocellulose membrane (Bio-Rad, United Kingdom).
Membranes were blocked with 3% (w/v) skimmed milk
powder in PBS (without Ca/Mg) with 0.1% Tween-20 (PBS-T),
overnight at 4◦C.
For CFTR, blots were incubated with 2 µg/ml “Mr. Pink”
rabbit polyclonal antibody (kindly provided by Prof. Ineke
Braakman, Utrecht University through the CFTR Folding
Consortium, United States) diluted 1:500 in PBS-T. Blots were
incubated with antibody for 1 h at room temperature (RT),
washed and incubated with 0.05 µg/ml goat anti-rabbit-HRP
(Dako) for 1 h at RT.
For Nrf-2, membranes were stained with 1 µg/ml rabbit
polyclonal anti-Nrf2 (Santa Cruz) in blocking buffer for 1 h
at RT, washed in PBS-T, and incubated with 0.125 µg/ml goat
anti-rabbit-HRP (Dako) for 1 h at RT.
For p-c-Jun, membranes were stained with 0.2 µg/ml rabbit
polyclonal anti-p-c-Jun [(Ser 63/73) Santa Cruz] overnight at 4◦C
in blocking buffer, and then 0.125 µg/ml goat anti-rabbit-HRP
(DAKO) for 2 h at RT.
After washing in PBS, blots were incubated for 5 min in the
dark with chemiluminescence substrate (Promega), followed by
detection of the bands with ChemiDocTM MP System (Bio-Rad).
The bands were normalized to β-actin in the samples, which
was detected after stripping with Restore Western Blot Stripping
Buffer (Thermo Fisher, United Kingdom) for 15 min and re-
probing membranes with rabbit polyclonal anti-β-actin for 1 h
at RT followed by 1 h incubation at RT with 0.05 µg/ml goat
anti-rabbit HRP (DAKO). Bands were quantified using scanning
densitometry and Quantiscan software.
Preparation of Supernatants and Cell Lysates for
Quantification of IL-8, VEGF, SOD-2 and Catalase by
ELISA
Supernatants from HLMVECs grown in 24-well plates were
cleared by centrifugation (1500 RCF for 10 min at 4◦C).
Cells were lysed for 10 min on ice in hypotonic buffer
(20 mM NaCl, 1% Triton X-100, and 20 mM Tris-base,
pH 7.4), containing Complete protease inhibitors (Roche),
and protease inhibitor cocktail I (Calbiochem). Lysates were
centrifuged at 5000 RCF for 10 min at 4◦C and samples
stored at −80◦C prior to analysis. IL-8 and VEGF were
measured using Duo-Set ELISA kits (R&D Systems) according
to the manufacturer’s instruction. Mitochondrial Mn-dependent
superoxide dismutase (SOD-2) and catalase were quantified
in neat cell lysates using ELISA kits (AbCam) according to
manufacturer’s instructions, with standard curves prepared in the
range 7.8–500 ng/ml.
Measurement of Intracellular ROS and H2O2
Human lung microvascular endothelial cells were seeded in
35 mm dishes for live cell imaging (25 × 104 cells/dish), and
HLMVECs and 16HBEs were seeded (8 × 103/well/100 µl)
for quantification of ROS in 96-well plates coated with
collagen IV and incubated overnight. In some experiments,
NAC (10 mM) was added for 3 h in FGM before adding
the ROS detector, carboxy-H2DFFDA (5-(and-6)-carboxy-2′,7′-
difluorodihydrofluorescein diacetate, (Invitrogen) in serum-free
HBSS (+Ca/Mg) at 10 µM for 30 min. Cells were washed
and incubated for 30 min in FGM, before being challenged
with GlyH-101 and TNF-α for 5, 10, and 30 min in FGM.
Changes in relative fluorescent units (1RFU) were compared
with cells treated with 0.1% DMSO or media alone, as controls
for GlyH-101 and TNF-α, respectively, and designated 100%
at each time point. In some experiments, the mitochondrial
targeting antioxidant MitoQ was added at 1 µM for 30 min
in FGM prior to challenge of the cells with GlyH-101 for
5 min. Plates were read at 37◦C in 5% CO2, Polar Star Optima
plate reader, (BMG Labtech), with excitation at 485 nm and
emission at 520 nm. For live cell imaging, dishes were examined
on a LSM 710 confocal microscope (ZEISS) with immersion
objectives and stage with temperature control, but without
atmospheric control.
Hydrogen peroxide (H2O2) was measured in HLMVECs
seeded at 5 × 104 cells/well/300 µl FGM in wells of 24-
well plates, incubated in the absence and presence of 10 µM
diphenyleneiodonium chloride (DPI) in FGM for 1 h, before
challenge with CFTR inhibitor GlyH-101 (20 µM) and control
DMSO (0.1%) for 5, 10, 30 min. Cells were lysed in 125 µl
of hypotonic lysis buffer [20 mM NaCl, 1% Triton X-100,
20 mM Tris-base, and pH to 7.4, with protease inhibitors
(Calbiochem), and sodium azide (0.1% w/v), to inhibit catalase
and peroxidase activity] and H2O2 quantified against an H2O2
standard in the range 3.125–200 µM using the Amplex Red assay
(Chen et al., 2008).
Immunocytochemistry for CFTR, Nrf2, NF-κB and
Phospho-c-Jun
HLMVECs, 16HBE or HEK293 cells in collagen-coated eight-
well chamber slides were fixed in paraformaldehyde (4%) and
permeabilized with Triton X-100 (0.1%). No primary antibody
controls were included for each analysis.
For CFTR staining, non-specific antibody-binding sites were
blocked with BSA (2%, for 16 h at 4◦C) and HLMVECs, 16HBE
or HEK293 cells incubated with rabbit anti-CFTR antibody “Mr.
Pink” (1/500), followed by goat anti-rabbit antibody conjugated
to Alexa Fluor-555 (2 µg/ml; Molecular Probes).
For NF-κB localization, non-specific antibody-binding sites
were blocked with rabbit serum (5%, for 1 h) and HLMVECs
incubated with mouse anti-p65 (4 µg/ml; Santa Cruz), for 16 h at
4◦C, followed by rabbit anti-mouse antibody conjugated to Alexa
Fluor-488 (2 µg/ml; Molecular Probes) for 1 h at RT.
For Nrf2 staining, HLMVECs were blocked with 5% goat
serum overnight at 4◦C, then rabbit polyclonal anti-Nrf2 (Santa
Cruz) at 4 µg/ml was added for 1 h at 4◦C, followed by
Alexa Fluor-555 goat anti-rabbit IgG (2 µg/ml; Molecular
Probes) for 1 h at RT.
For phospho-c-Jun staining HLMVECs were blocked with
5% goat serum overnight at 4◦C, then rabbit anti-p-c-Jun [(Ser
63/73), Santa Cruz] at 0.8 µg/ml was added for 1 h at 4◦C,
followed by goat anti-rabbit Alexa Fluor-555 (Molecular Probes)
at 2 µg/ml for 1 h at RT.
Nuclei were stained with 5 µg/ml Hoechst 33342 (Molecular
Probes) for 10 min, and slides mounted in Fluor-Preserve
Reagent for imaging with a LSM 710 confocal microscope (Zeiss).
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RNA Extraction and Reverse Transcription
Total RNA was extracted using ReliaPrep RNA Cell Miniprep
System (Promega) according to manufacturers’ instructions. The
concentration and purity (absorbance ratios at 260/230 and
260/280 of ≥2.0) of RNA in samples was determined using a
Nanodrop spectrophotometer. RNA was then reverse transcribed
into cDNA using the first step of the GoTaq 2-Step RT-qPCR
System (Promega) and either stored at −20◦C or immediately
used in quantitative PCR.
Quantitative Real-Time Polymerase Chain Reaction
(qRT-PCR)
Cystic fibrosis transmembrane conductance regulator, IL-8 and
β-actin transcripts were amplified from cDNA (1 µg), using the
following primers: CFTR (105 bp) sense 5′- ATG CCC TTC GGC
GAT GTT TT -3′and antisense 5′- TGA TTC TTC CCA GTA
AGA GAG GC -3′;
IL-8 (194 bp) sense 5′- TTT TGC CAA GGA GTG CTA AAG
A -3′ and antisense 5′- AAC CCT CTG CAC CCA GTT TTC -3′:
and β-actin (93 bp) sense 5′- CGC GAG AAG ATG ACC CAG
AT -3′ and antisense 5′- GCC AGA GGC GTA CAG GGA TA -3.
The cycles for the qRT-PCR were: 2 min at 95◦C, then 35 cycles
for quantitation of IL-8 expression and 40 cycles for detection of
CFTR mRNA of 10 s at 95◦C, 20 s at 62◦C, and 60 s at 72◦C.
Data were collected using a LightCycler 96 (Roche Diagnostics
International Ltd.).
For nested or two-step, quantitative PCR, a 526 bp region of
CFTR was first amplified using primers: sense 5′- ACA GCG
CCT GGA ATT GTC AGA C -3′and antisense 5′- AGC GAT
CCA CAC GAA ATG TGC C -3′, followed by a second round
of amplification using the CFTR-specific primers and conditions
used in the single-step quantitative PCR.
To exclude the possibility of amplification from
contaminating genomic DNA during the qRT-PCR reaction,
we utilized a DNAse step in the ReliaPrep protocol during
mRNA extraction, and primers were designed to span at
least one or more large (>20,000 bp) introns, precluding
amplification from genomic DNA directly. Negative control
reactions, not including template cDNA (no template control)
or reverse transcriptase (“-RT,” or no amplification control),
were also performed and accepted when the threshold value
(Ct) was at least five cycles greater than the experimental
amplifications. Measurements were performed in duplicate
and accepted if the difference between the Ct values of the
duplicates was less than 1. The generation of a single product
of appropriate size was routinely checked by the presence of
a single melt peak and by agarose gel electrophoresis. Data
were analyzed using Roche LightCycler software. A relative
expression method was implemented, normalizing the data by
the internal control β-actin and expressing the final result relative
to the control group.
Electroporation and CFTR Silencing
Electroporation were used to introduce small interfering RNA to
target the CFTR gene in HLMVECs. HLMVECs (0.75 × 106)
were suspended in 100 µl of OptiMEM medium and transferred
to a sterile cuvette for the NEPA21 electroporator (NepaGene)
and 2 µl of siRNA for CFTR or validated non-targeting siRNA
pool (50 µM) was added to a final concentration of 1 µM. For
CFTR siRNA (ON-TARGET plus Human CFTR (1080) siRNA-
SMART pool (Dharmacon) was used, which consists of a mixture
of four siRNA with target sequence as the following:
1-GAACACAUACCUUCGAUAU
2-GUACAAACAUGGUAUGACU
3-GUGAAAGACUUGUGAUUAC
4-GCAGGUGGGAUUCUUAAUA
The cells were electroporated according to the pulse settings in
Table 1.
After electroporation cells were transferred to the wells of a
collagen-coated 6 well plate at a final concentration of 1.5 × 106
cell/well/2 ml of FGM. The medium then was changed every
24 h, for a total of 72 h, then the supernatants for the last
24 h were harvested and processed and used to analyze IL-8
concentrations by ELISA.
Statistical Analysis
Statistical analysis was carried out using GraphPad Prism version
8. Data is presented graphically as mean ± SEM, and analyzed
by one-way or two-way ANOVA with two-tailed post hoc tests
for multiple comparisons as appropriate and as indicated in the
Figure legends. A directional one-tailed t-test was applied in the
case of the hypothesized increase in CFTR expression following
inhibition of CFTR activity (Figure 1F). Multiplicity adjusted p
values are given in the text to four decimal places.
The relative effect size, Cohen’s d, was determined
by calculating the mean difference between two groups
and dividing the result by the pooled standard deviation.
Cohen’s d = (M2−M1)/SDpooled, where:
SDpooled =
√
((SD12 + SD22)/2), and Cohen’s d > 0.8 is
considered a large effect size.
RESULTS
CFTR Expression
Western blotting and RT-PCR were used to confirm CFTR
expression in HLMVEC under the cell culture conditions used
TABLE 1 | Electroporation pulse settings.
Poring pulse Transfer pulse
V Length ms Interval ms No. D. Rate (%) Polarity V Length ms Interval ms No. D. Rate (%) Polarity
170 2.5 50 2 10 + 20 50 50 5 40 ±
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FIGURE 1 | CFTR expression in HLMVECs. (A) Immunoblot of CFTR in whole cell extracts of HLMVEC, 16HBE and HEK-293 cells. All data are representative of
that obtained in at least three independent experiments. (B) Immunolocalization of CFTR in HLMVEC, 16HBE and HEK-293 cells (the control refers to the no-primary
antibody negative control). All images were acquired and displayed under identical conditions. (C) RT-PCR amplification of CFTR (light gray), β-actin (solid) and
reverse-transcription negative control (-RT CFTR, dotted line) in HLMVECs, and CFTR in 16HBE cells (positive control, dark gray). (D) Gel analysis of CFTR cDNA
amplified from HLMVEC, 16HBE mRNA and -RT control following single and nested RT-PCR. (E,F) CFTR expression in HLMVECs cell lysate by western blot after
16 h incubation with GlyH-101 (20 µM) and DMSO (0.1%) vehicle control. Data were normalized to β-actin, numbers expressed as average of three independent
experiments. Each experiment was conducted on HLMVECs obtained from three different donors (∗p < 0.05 for the difference between GlyH-101 and control). The
scale bar represents 50 µm.
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in these experiments, including growth on collagen IV coated
cultureware. CFTR could be detected on western blot as two
high molecular weight bands in HLMVEC lysates, the partially
glycosylated band B (140 kDa) and fully mature band C
(170 kDa) (Figure 1A). However, the level of expression was
highly variable between preparations. In separate experiments,
the same CFTR protein bands were detected in 16HBE, but not
in HEK293 cells. Levels of CFTR detected by IHC appeared to
be lower in HLMVECs than in the 16HBE bronchial epithelial
cell line and, in addition to the plasma membrane, CFTR was
detected in association with intracellular organelles possibly
the endoplasmic reticulum around the nucleus (Figure 1B).
Additionally, expression of CFTR mRNA was detected in
HLMVECs (1CT = 25.35 ± 0.55, n = 3), although at
much lower levels that in 16HBEs (1CT = 3.78 ± 0.53,
n = 3; p < 0.0001), when normalized to housekeeping β-actin
expression at threshold of 0.02 1RFU (Figure 1C). The
expression of CFTR mRNA In HLMVECs was confirmed by
nested PCR (Figure 1D) which increased the intensity of the
expected 100 bp CFTR product observed in single round PCR
while the expected 500 bp product was faintly detected.
In view of previous reports of the negative regulation of
CFTR expression by CFTR activity (Wang et al., 2016), we
tested the hypothesis that CFTR inhibition would increase
CFTR expression. Indeed, the abundance of CFTR in cells
treated for 16 h with GlyH-101 (20 µM) was significantly
higher (p = 0.035, one-tailed t-test) with a large effect size
(Cohen’s d = 1.55) compared to control cells treated with
DMSO (0.1%) (Figures 1E,F).
GlyH-101 and HLMVEC Viability
In order to investigate the effect of the CFTR inhibitor and
the vehicle control on metabolic activity as a measure of cell
cytotoxicity, cells were grown in medium (FGM) alone, or
incubated with GlyH-101 (5, 10, 20 µM) or DMSO (0.1%), as the
vehicle control, for the times indicated (Figure 2) and metabolic
activity measured using the MTT assay. Data was normalized to
the metabolic activity of cells grown in medium alone. Incubation
FIGURE 2 | Effect of GlyH-101 on HLMVEC viability. HLMVECs were grown in
FGM medium alone (medium), or treated for 16, 24, and 48 h with CFTR
inhibitor GlyH-101 at 5, 10, and 20 µM or 1% DMSO as vehicle control.
Results were normalized for the cells grown in medium alone, and data for the
effect of GlyH-101 compared with DMSO (0.1%) vehicle control data. Data
were expressed as mean ± SEM (**p value < 0.01 comparing GlyH-101
(20 µM) to DMSO (0.1%) at 48 h, n = 3 independent experiments). Data were
analyzed with two-way ANOVA and Tukey’s multiple comparison test.
of cells with GlyH-101 at concentrations of 5–20 µM for up to
24 h had no significant effect on HLMVEC metabolic activity
(MTT reduction) compared to the vehicle control (Figure 2).
After 48 h incubation with the highest (20 µM) GlyH-101
concentration, the significant (p = 0.002) decrease in MTT
reduction (74.2 ± 15.4%) compared with the DMSO control
(123.6± 22.0%) was associated with a reduction in the number of
cells adherent to the plate. Experiments using GlyH-101 to inhibit
CFTR were therefore conducted over periods of up to 24 h.
CFTR Activity
Cystic fibrosis transmembrane conductance regulator activity
was detected as membrane depolarization at baseline, and in
response to IBMX plus forskolin leading to increased uptake
and fluorescence of intracellular FLIPR Blue, that could be
inhibited by GlyH-101 (Maitra et al., 2013). The significant
(p = 0.0002) inhibitory effect (Cohen’s d = 1.32) of GlyH-101 on
control cells indicates constitutive activity of CFTR in HLMVECs
(Figure 3A). This was not seen in HEK293 cells used as a negative
control or 16HBE cells used as a positive control. The cAMP-
elevating agent forskolin (an adenylate cyclase activator) together
with IBMX (a cAMP-phosphodiesterase inhibitor) strongly
(p < 0.0001) stimulated HLMVEC membrane depolarization
in all cells (Figure 3B, black bars) compared to baseline
(Figure 3A, black bars). CFTR activity was measured as the
increase in membrane depolarization (increase in 1 RFU) that
was significantly inhibited by GlyH-101 (20 µM) (Figure 3B,
gray bars). In HLMVEC, GlyH-101 significantly (p = 0.0495)
inhibited membrane depolarization by 34% (Cohen’s d = 1.17).
The depolarization response of 16HBE cells was significantly
(p = 0.0095) greater than that of HLMVECs and was significantly
(p = 0.0068) inhibited 26.4% (Cohen’s d = 1.08) by GlyH-101.
This decrease in fluorescence was attributed to inhibition of
CFTR activity. HEK293 cells that do not express CFTR (Friard
et al., 2017) showed a greater depolarization in response to
forskolin/IBMX than HLMVECs, but there was no significant
inhibitory effect of GlyH-101 (Figure 3B) and no effect on
unstimulated control cells (Figure 3A).
CFTR and Oxidative Stress
In view of previous reports of the effect of dysfunctional epithelial
CFTR on increased intracellular H2O2 (Chen et al., 2008), we
investigated the effect of CFTR inhibition on the generation of
intracellular ROS and, specifically, H2O2 levels. Using live-cell
imaging, low levels of intracellular ROS were observed at time
zero, which increased over 30 min after treating the cells with
GlyH-101 (Figure 4A). However, using a quantitative approach
to measuring ROS generation, a faster response was detected
in stimulated cells compared to unstimulated control cells
(Figure 4B). The slower response during live cell imaging may
reflect the absence of atmospheric control during the experiment.
Both TNF-α, included as a positive control, and GlyH-101
induced a significant (p = 0.0012 and p = 0.0004, respectively)
increase in ROS of 165.2 ± 35.1% and 170 ± 11.5% compared to
unstimulated control cells at 5 min. The response to GlyH-101
was sustained over 30 min and was significantly higher than the
response to TNF-α at 10 and 30 min (p = 0.003 and p = 0.0173,
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FIGURE 3 | CFTR activity in HLMVECs at baseline and following cAMP-dependent activation. CFTR activity was measured at baseline (A) and following
cAMP-dependent activation (B) of HLMVECs, non-CFTR expressing HEK-293 cells and CFTR expressing 16HBE cells for comparison. CFTR activity at baseline
was measured as a decrease in relative fluorescence units (1RFU) following treatment of cells with the CFTR inhibitor GlyH-101 (20 µM, gray bars), reflecting
membrane hyperpolarization and decreased uptake of FLIPR compared to cells treated with 0.1% DMSO vehicle control (black bars). Activation of CFTR (B) was
measured as an increase in fluorescence (1RFU) following membrane depolarization of HLMVECs, HEK-293, and 16HBE cells activated with forskolin (100 µM) plus
IBMX (1000 µM) (F/I) for 2 min in the absence (black bars) and presence (gray bars) of GlyH-101 (n = 3 independent experiments, each carried out in quadruplicate).
Data were analyzed by two-way ANOVA and Holm-Sidak multiple comparisons test (∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 for the comparisons indicated).
respectively), while the response to TNF-α was back to control
levels at 10 min (Figure 4B).
N-acetyl cysteine (10 mM), added 3 h before GlyH-101, had no
effect on ROS production at 5 and 10 min following stimulation
with GlyH-101. After 10 min, ROS production in response to
GlyH-101 was 164.5 ± 9.9% of the control value, and in the
presence of NAC was still 156.9± 50% of the control value (n = 6).
However, NAC (10 mM) not only reversed the effect of GlyH-101
on ROS levels at 30 min, but also significantly (p = 0.005) reduced
the level of ROS to 42.8 ± 28.1% fluorescence intensity, below
that observed in control cells (Figure 4B).
H2DFFDA detects intracellular oxidative stress rather than a
specific reactive species (Eruslanov and Kusmartsev, 2010). We
therefore measured H2O2, one of the major ROS in cells. H2O2
was not detected in supernatants, but intracellular H2O2 was
significantly (p = 0.0022) increased (Cohen’s d = 4.39) following
30 min treatment with GlyH-101 (36.1 ± 2.7 µM) compared to
control (13.2 ± 2.5 µM), with no significant changes at earlier
time points (Figure 4C). Incubation of cells with 10 µM DPI
for 1 h prior to and during GlyH-101 challenge had no effect on
H2O2 concentrations.
Intracellular SOD-2 protein levels were significantly increased
at 16 h (p = 0.05, Cohen’s d = 1.58) and at 24 h (p = 0.0054,
Cohen’s d = 2.63) following CFTR inhibition (Figure 4D). No
significant changes in catalase protein levels were observed over
24 h (data not shown).
The staining pattern observed during live cell imaging of ROS
was punctuate (Figure 4A), which suggested a mitochondrial
source of ROS. However, the mitochondrial-targeting antioxidant
MitoQ had no effect in HLMVEC or 16HBE cells on ROS
production, measured as a change in 1RFU of carboxy-
H2DFFDA over 5 min following challenge with GlyH-101
(Figures 4E,F). GlyH-101 induced a significant increase in ROS
in HLMVECs in the absence (p = 0.0043, Cohen’s d = 1.65) and
presence (p = 0.0042) of MitoQ, and in the 16HBE bronchial
epithelial cell line in the absence (p = 0.0275, Cohen’s d = 1.3) and
presence (p = 0.0474) of MitoQ, which had no significant effect.
CFTR and Nrf-2 Expression
Chen et al. (2008) reported significantly reduced Nrf2 expression
in CF epithelia and in normal epithelial cells treated with the
CFTR inhibitor CFTRinh-172 (Chen et al., 2008). Therefore,
Nrf2 expression in HLMVECs was investigated following CFTR
inhibition with GlyH-101 (20 µM) for up to 24 h. IHC
demonstrated that Nrf2 was mostly absent from the cytoplasm
after 24 h incubation with GlyH-101, compared to control cells
(Figure 5A). The overall abundance of Nrf2 was significantly
(p = 0.0425) decreased at 6 h and had decreased further still at
16 h (p = 0.0032) and by 70.8± 11.6% at 24 h, (p = 0.0034, Cohen’s
d = 4.82), compared to control cells (Figures 5B,C).
CFTR and VEGF Expression
Since ROS induce the expression of endothelial VEGF (Kim and
Byzova, 2014), we investigated the effect of GlyH-101 on VEGF
levels in HLMVEC culture supernatants. Initial experiments
established that GlyH-101 (5, 10, 20 µM) increased endothelial
VEGF expression over 16 h, with a significant effect at 20 µM
GlyH-101 (Figure 6), but not at lower concentrations (data not
shown). GlyH-101 (20 µM) significantly (p = 0.0375, Cohen’s
d = 2.95) increased VEGF concentration in the supernatants
(202.1 ± 22.1 pg/ml) compared to control (74.24 ± 11.8 pg/ml)
over 16 h (Figure 6A). TNF-α, alone, did not have a significant
effect on VEGF levels, but further significantly (p = 0.0019,
Cohen’s d = 2.01) increased the VEGF response to GlyH-101
to 394.5 ± 50.4 pg/ml. Treatment of cells with NAC (5 mM)
significantly (p = 0.0056) reduced VEGF levels in the presence
of GlyH-101 plus TNF-α to 105.6 ± 21.8 pg/ml, which was
thus found not significantly higher than control levels (data not
presented graphically).
In cultured airway epithelial cells, treatment with CFTR
inhibitors triggered EGFR phosphorylation and activation that
was required for VEGF synthesis (Martin et al., 2013). We
therefore investigated the effect of EGFR inhibition on VEGF
synthesis in HLMVECs. Pre-treatment with the EGFR tyrosine
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FIGURE 4 | Oxidative stress in HLMVECs following CFTR inhibition with GlyH-101. (A) Intracellular ROS in HLMVECs using live cell imaging. Intracellular ROS in
HLMVECs detected using carboxy H2-DFFDA. GlyH-101 (20 µM) was added and the fluorescence detected at 0, 10, and 30 min. Scale bar 50 µm. Images
representative of duplicate wells in a single experiment. (B) Quantification of intracellular ROS in HLMVECs using carboxy-H2DFFDA. HLMVECs were incubated for
5–30 min in the absence and presence of GlyH-101 (20 µM) and TNF-α (10 ng/ml) and ROS detected by intracellular DFFDA. The experiments were conducted in
triplicate, n = 6 independent experiments for GlyH-101 in the absence and presence of 10 mM NAC, and n = 3 for TNF-α. Control values at each time point were
designated 100% (filled circles). Data points represent the mean ± SEM. Results were analyzed with two-way ANOVA and Tukey’s multiple comparisons test. (**** p
value < 0.0001, *** p value < 0.001) comparing GlyH-101 to control and (** p value < 0.01) comparing TNF-α to control, (††, p value < 0.01, † p value < 0.05
comparing GlyH-101 and TNF-α). (C) Quantification of intracellular H2O2 using Amplex Red. HLMVECs were treated with GlyH-101 for 5–30 min, and H2O2
measured in cell lysates using Amplex Red reagent. ** p value < 0.01 in comparison to DMSO after 30 min, (n = 4). Data were expressed as average ± SEM and
analyzed with two way ANOVA and Tukey’s post hoc test. (D) Intracellular SOD2. SOD2 was measured by ELISA in HLMVECs cell lysates following CFTR inhibition
with GlyH-101 (20 µM). Data were analyzed with one way ANOVA and Dunnett’s test, n = 3 (* p < 0.05, ** p value < 0.01 compared to DMSO control at 24 h).
(E) Quantification of intracellular ROS in HLMVECs using carboxy-H2DFFDA. HLMVECs were incubated for 30 min with/without MitoQ (1 µM) followed by 5 min
incubation with GlyH-101 (20 µM) and ROS detected by intracellular DFFDA. The experiments were conducted in quadruplicate, n = 3 independent experiments.
(** p value < 0.01 for the comparisons indicated). Data were analyzed by two-way ANOVA with Tukey’s multiple comparison post hoc test. RFU, relative fluorescence
units. (F) Quantification of intracellular ROS in 16HBEs using carboxy-H2DFFDA. 16HBEs were incubated for 30 min with/without MitoQ (1 µM) followed by 5 min
incubation with GlyH-101 (20 µM) and ROS detected by intracellular DFFDA. The experiments were conducted in quadruplicate, n = 3 independent experiments.
(* p < 0.05 for the comparisons indicated). Data were analyzed by two-way ANOVA with Tukey’s multiple comparison post hoc test. RFU, relative fluorescence units.
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FIGURE 5 | The effect of CFTR inhibition on Nrf-2 expression. The effect of CFTR inhibition on Nrf2 expression in HLMVECs over 24 h was investigated by
immunocytochemistry (A) and by western blot (B,C). (A) CFTR inhibition by GlyH-101 (20 µM) results in loss of cytosolic Nrf2 (arrows in control) with residual Nrf2 in
nuclei. Scale bar 50 µm. Images are representative of two independent experiments. (B,C) Nrf2 was detected on western blot as an 85 kDa band in control cells
(lane C) at 24 h (B), this value was significantly reduced by 70% with GlyH-101 over 24 h (C). Bars indicate mean ± SEM (* p < 0.05, *** p value < 0.001) for
comparison with 24 h control, n = 3 independent experiments. Data were analyzed by one-way ANOVA with Dunnett’s post hoc test.
kinase inhibitor AG1478 (10 µM) caused a non-significant
increase in VEGF levels at 16 h (results not shown). However,
a significant (p< 0.0001) increase in VEGF (481.6± 59.2 pg/ml)
was seen following EGFR inhibition with AG1478, alone,
compared to control (13.48 ± 2.9 pg/ml) over 24 h (Figure 6B).
Although GlyH-101 alone had no significant effect on VEGF
synthesis over 24 h, AG1478 increased VEGF synthesis in the
presence of GlyH-101 (p < 0.0001), and in the presence of
both the CFTR inhibitor and EGFR inhibitor VEGF levels were
598.8 ± 63.7 pg/ml. Addition of TNF-α to GlyH-101 at this time
point induced a small significant (p = 0.046) increase in VEGF
levels, and addition of AG1478 further significantly (p < 0.0001)
increased VEGF levels in the presence of GlyH-101 plus TNF-α.
CFTR and IL-8 Expression
Functional CFTR was reported to limit bronchial epithelial
expression of IL-8 (Perez et al., 2007). We therefore investigated
the effect of CFTR inhibition on IL-8 expression by HLMVECs.
Control, unstimulated, HLMVECs expressed IL-8 that was
predominantly in soluble form and released into supernatants
(Figure 7A). The CFTR inhibitor GlyH-101 (20µM) significantly
increased IL-8 protein levels in both supernatants (p = 0.0359)
and HLMVEC cell lysates (p = 0.0234) (Figure 7A). This effect
was not seen with GlyH-101 added at 5 µM and 10 µM.
IL-8 concentrations were significantly (p < 0.0001) higher in
supernatants than lysates under all conditions. TNF-α (10 ng/ml)
further significantly (p < 0.0001) increased IL-8 levels in the
presence of GlyH-101 (20 µM) in both fractions over 16 h. In the
presence of TNF-α, GlyH-101 (20 µM) significantly increased IL-
8 levels in cell lysates (p = 0.0193) and supernatants (p = 0.0047)
compared to TNF-α alone.
Over a 24-h time course, TNF-α (10 ng/ml) and the
combination of TNF-α (10 ng/ml) plus GlyH-101 (20 µM)
significantly (p < 0.0001) increased supernatant IL-8 levels at
both 16 h and 24 h (Figure 7B). The response to TNF-α alone
plateaued at 16 h (Figure 7B), but the combination of GlyH-101
plus TNF-α significantly increased IL-8 levels at 16 h (p = 0.0043)
and at 24 h (p< 0.0001) compared to the effect of TNF-α alone.
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FIGURE 6 | The effect of CFTR inhibition on VEGF concentrations in HLMVEC
culture supernatants. (A) VEGF concentration after 16 h CFTR inhibition with
GlyH-101 (20 µM), in the absence and presence of TNF-α (10 ng/ml). VEGF
was measured by ELISA, and concentrations expressed as average ± SEM
(* p value < 0.05, ** p value < 0.01, *** p value < 0.001 for the comparisons
indicated). Data were analyzed with one-way ANOVA test and Tukey’s multiple
comparison test, n = 6 independent experiments, each carried out in
triplicate. (B) The effect of AG1478 on VEGF concentration alone, and after
24 h CFTR inhibition with GlyH-101 (20 µM) in the absence and presence of
TNF-α. VEGF was measured by ELISA, and concentrations expressed as
average ± SEM (**** p value < 0.0001 for the comparisons indicated,
* p value < 0.05 for TNF + Gly compared to the control value). Data were
analyzed with one-way ANOVA test and Tukey’s multiple comparison test,
n = 3 independent experiments, each carried out in triplicate.
AG1478 (10 µM) and NAC (5 mM) significantly (p = 0.0028
and p = 0.0444, respectively) inhibited the response to the
combination of TNF-α plus GlyH-101 at 24 h.
The increase in protein concentration mirrored the increase in
IL-8 mRNA expression following 16 h incubation with GlyH-101
(20 µM) and TNF-α (10 ng/ml), alone and in combination
(Figure 7C). The normalized relative expression of IL-8 mRNA
was significantly (p = 0.0258, Cohen’s d = 17.82) increased in the
presence of GlyH-101 alone. GlyH-101 also further significantly
(p = 0.0004, Cohen’s d = 3.72) enhanced the response to TNF-α.
Specificity of GlyH-101
Melis et al. (2014) reported non-specific inhibitory effects of
GlyH-101 on volume-sensitive outwardly rectifying chloride
conductance (VSORC), also termed volume-regulated anion
channel current (VRAC), and calcium-activated chloride
conductance (CaCC) in murine cell lines expressing CFTR
(Melis et al., 2014). More recently, Friard et al. (2017) also
reported inhibitory effects of GlyH-101 on VRAC conductance
in the immortalized human embryonic kidney cell line, HEK-293
cells, with an IC50 of 9.5 µM and 80% inhibition at 20 µM
(Friard et al., 2017).
HEK-293 cells, unlike endothelial cells, do not express CFTR
or the calcium-activated chloride ion channels anoctamin-1 and
anoctamin-2 (ANO1/2, also termed TMEM16A and TMEM16B,
respectively) (Friard et al., 2017). Therefore to investigate
whether the pro-inflammatory effects of GlyH-101 effects on
HLMVEC were due to inhibitory effects on VRAC activity, HEK-
293 cells were incubated with 20 µM GlyH-101 for 24 h and
IL-8 levels measured in cell culture supernatants. Because HEK-
293 cells express moderate levels of endogenous TNFα receptors
(Greco et al., 2015), TNFα (10 ng/ml) was used as a positive
control. TNFα (10 ng/ml) significantly (p < 0.0001, Cohen’s
d = 42.1) increased IL-8 concentrations in HEK-293 cell culture
supernatant compared to control levels (Figure 8A), whereas
GlyH-101 had no effect, indicating that effects of GlyH-101 on
IL-8 expression are not mediated by VRAC.
This was confirmed using the potent (IC50 4.8 µM)
and specific VRAC inhibitor DCPIB (4-(2-butyl-6,7-dichlor-
2-cyclopentyl-indan-1-on-5-yl) oxybutyric acid (Friard et al.,
2017), in cultures of HLMVECs with GlyH-101 (20 µM) and
TNFα (10 ng/ml) as positive controls. Both TNFα (p < 0.0001,
Cohen’s d = 16.73) and GlyH-101 (p = 0.017, Cohen’s d = 4.7)
significantly increased IL-8 in culture supernatants, but DCPIB
at 20 µM had no effect (Figure 8B).
Additionally, the potent (IC50 77 nM) TMEM16A-specific
inhibitor Ani9 (2-(4-chloro-2-methylphenoxy)-N-[(2-
methoxyphenyl)methylideneamino]-acetamide), that lacks
inhibitory activity against CFTR and VRAC (Seo et al., 2016)
did not induce significant IL-8 expression by HLMVECs at the
relatively high concentration of 10 µM (Figure 8B).
Effect of CFTR Gene Silencing
The anti-inflammatory function of endothelial CFTR was
confirmed using a siRNA approach to CFTR gene silencing.
A significantly (p = 0.041, Cohen’s d = 1.84) higher concentration
of IL-8 was measured in the supernatants of HLMVECs
transfected with CFTR siRNA compared with cells transfected
with non-targeting siRNA. The non-targeted cells yielded
160.01 ± 17.2 pg/ml IL-8 in HLMVEC supernatants,
while silencing of CFTR (siCFTR) in HLMVECs gave
265.4± 36.7 pg/ml IL-8 in the supernatant (Figure 9) confirming
constitutive CFTR activity in HLMVECs.
CFTR and Inflammatory Cell Signaling
Functional CFTR was reported to be a negative regulator of
NF-κB and inflammatory cell signaling (Vij et al., 2009). We
therefore investigated the effect of CFTR inhibition on activation
of NF-kB and AP-1, two key ROS-dependent signaling pathways
leading to IL-8 expression (Hoffmann et al., 2002), with TNF-
α (10 ng/ml) as a positive control stimulus. While TNF-α
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FIGURE 7 | IL-8 in HLMVEC cells and supernatants. (A) Concentration response curve for CFTR inhibitor GlyH-101 in the absence and presence of TNF-α
(10 ng/ml) for 16 h. GlyH-101 at 20 µM significantly increased IL-8 in supernatant, cell lysate, with and without TNF-α (* p < 0.05, ** p < 0.01) comparing GlyH-101
with control for each condition using one-way ANOVA (n = 3). (B) Time course for the effect of TNF-α (10 ng/ml) alone and in the presence of GlyH-101 (20 µM) on
IL-8 levels in HLMVEC supernatants. (**** p < 0.0001 compared to 24 h control, FGM), (†† value < 0.01, † † †† value < 0.0001 compared to TNF-α alone), (n = 3).
AG1478 (10 µM, filled triangle) and NAC (5 mM, open circle) significantly (p < 0.01 and p < 0.05, respectively) inhibited the response to the combination of TNF-α
plus GlyH-101 at 24 h. Numbers were expressed as mean ± SEM. The data were analyzed with two-way ANOVA and Tukey’s multiple comparison test, or one-way
ANOVA for the effects of AG1478 and NAC on the response to the combination of TNF-α plus GlyH-101. (C) Relative changes in IL-8 mRNA levels normalized to
β-actin (2-delta delta Ct values), following 16 h incubation with GlyH-101 (20 µM) and TNF-α (10 ng/ml), alone and together, compared to DMSO (0.1%) control,
n = 3. (* p < 0.05 comparing GlyH-101 with DMSO control, and *** p < 0.001 comparing TNF-α + GlyH-101 with TNF-α alone).
clearly stimulated nuclear translocation of the NF-kB p65 subunit
(Figure 10A, panel 2), CFTR inhibition with GlyH-101 (20 µM)
had no effect (Figure 10A, panel 3). However, both GlyH-101
and TNF-α significantly (p = 0.0326 with Cohen’s d = 1.86
and p = 0.035 with Cohen’s d = 2.37, respectively) increased
phosphorylation of the AP-1 c-Jun subunit (Figures 10C1,C2)
and significantly (p = 0.0476 with Cohen’s d = 1.96, and
p = 0.0094 with Cohen’s d = 1.99, respectively) increased its
nuclear translocation (Figures 10B,D).
DISCUSSION
Summary of Key Findings
We have shown that lung microvascular endothelial cells
respond to CFTR inhibition with significantly increased levels
of ROS, increased IL-8, VEGF and SOD-2 expression, and a
significant 70% decrease in Nrf2 protein levels. GlyH-101, a
CFTR-specific inhibitor, increased IL-8 expression via ROS-
dependent activation of AP-1 signaling with increased nuclear
phospho-c-Jun in HLMVECs, but no evidence of NF-κB
activation. Further, CFTR inhibition enhanced TNFα-stimulated
IL-8 expression, which occurs via both AP-1 and NF-κB
signaling pathways. We show that dysfunctional CFTR enhanced
EGFR-dependent expression of IL-8, which was inhibited
using the EGFR tyrosine kinase specific inhibitor AG1478.
Conversely, the increased expression of VEGF following CFTR
inhibition was significantly enhanced in the presence of
AG1478, and in this respect these endothelial cells differ
from airway epithelial cells. Overall, the data indicate that
suppression of endothelial CFTR activity activates production of
intracellular ROS, and ROS-dependent signaling cascades leading
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FIGURE 8 | CFTR-specific inhibition mediates pro-inflammatory effects in HLMVECs. (A) non-CFTR expressing HEK-293 cells were incubated with GlyH-101
(20 µM) and TNF-α (10 ng/ml) as a positive control, and IL-8 was measured in culture supernatants by ELISA (n = 3) (**** p < 0.0001 compared to control).
(B) HLMVECs were cultured for 24 h in the absence and presence of the CFTR inhibitor GlyH-101 (20 µM), the calcium-activated chloride ion channel
Transmembrane Member 16A (TMEM16A)-specific inhibitor Ani-9 (10 µM), the Volume-Regulated Anion Channel (VRAC)-specific inhibitor DCPIB (20 µM) and
TNF-α (10 ng/ml) as a positive control, and IL-8 was measured in culture supernatants by ELISA (n = 3). Data were analyzed by one-way ANOVA with Dunnett’s
multiple comparisons post hoc test. (* p < 0.05 comparing GlyH-101 with control, and **** p < 0.0001 comparing TNF-α with control).
FIGURE 9 | CFTR gene silencing. CFTR gene silencing using siRNA in
HLMVECs induced a significant increase in IL-8 in supernatants. After
targeting CFTR mRNA for 72 h, the results were compared with non-targeting
siRNA as negative control. (*p < 0.05, n = 4 independent experiments, with
each experiment carried out in duplicate). Data were expressed as
mean ± SEM and analyzed by t-test.
to activation of nuclear transcription factors involved in IL-8
and VEGF synthesis.
CFTR Expression
Endothelial CFTR expression was confirmed in the present study,
but appeared to be lower in our model than previously reported
in HLMVECs (Tousson et al., 1998), possibly reflecting growth
on collagen IV, which is an exclusive component of basement
membranes that regulates endothelial cell function (Wang and
Su, 2011). Levels of expression varied greatly between HLMVEC
preparations, as reported for other tissues (Riordan et al., 1989),
and appeared to be largely associated with intracellular organelles
with punctate staining indicating localization in the endoplasmic
reticulum surrounding the nucleus, as previously reported in
endothelial cells (Tousson et al., 1998).
Since we found that the CFTR inhibitor GlyH-101 does
not activate endothelial NF-κB (Figure 10), the increased
expression of CFTR following CFTR inhibition is unlikely to
be via activation of the TNF-R adaptor molecule, TRADD,
and NF-κB activation, as has been previously described
in bronchial epithelial cells (Wang et al., 2016). However,
Nrf2 has an inhibitory effect on CFTR expression (Rene
et al., 2010) and repression of CFTR expression occurs
under conditions of prolonged oxidative stress in bronchial
epithelial cells (Zhang et al., 2015). Thus, the significantly
reduced levels of endothelial Nrf2 we detected in HLMVECs
following CFTR inhibition (Figure 5) may contribute to the
observed increase in endothelial CFTR expression following
treatment with GlyH-101.
However, the low levels of mature CFTR in the plasma
membrane were activated by the cAMP-elevating agents,
forskolin plus IBMX, to cause cell depolarization. This response
was inhibited by GlyH-101, a water-soluble glycine hydrazide
reported to bind to CFTR externally in the channel pore where,
at 10 µM, it rapidly and completely inhibited CFTR chloride
channel activity in human airway epithelial cells (Muanprasat
et al., 2004). The cAMP-elevating agents stimulated membrane
depolarization in both HLMVECs and 16HBEs and the non-
CFTR expressing HEK293 cells. Significant inhibition of the
response by GlyH-101 in HLMVECs and 16HBEs indicated
that depolarization was partly due to CFTR. However, other
cAMP-activated channels, such as cAMP-gated non-selective
cation channels (Nilius and Droogmans, 2001), which are not
inhibited by GlyH-101, may also contribute to membrane
depolarization in these cells.
CFTR and Oxidative Stress
Oxidative stress is a key contributor to vascular endothelial
dysfunction in people with CF (Tucker et al., 2019). In the present
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FIGURE 10 | The effect of GlyH-101 on cell signaling. (A) NF-κB immunocytochemistry of HLMVECS after 1 h of 1; DMSO (0.1%), 2; TNF-α (10 ng/ml), 3; GlyH-101
(20 µM). No primary antibody controls showed no positive staining. (B) p-c-jun immunocytochemistry of HLMVECs after 30 min of 1; DMSO (0.1%), 2; TNF-α
(10 ng/ml), 3; GlyH-101 (20 µM). No primary antibody controls showed no positive staining. (C) p-c-jun western blotting. (C1) image of whole cell lysate after treating
HLMVECs with DMSO (0.1%), TNF-α (10 ng/ml), GlyH-101 (20 µM) for 30 min. L; molecular weight ladder. (C2) quantification p-c-jun on western blots from three
independent experiments. Data were analyzed with one-way ANOVA and Fisher post hoc test. (* p < 0.05 compared with DMSO control, n = 3). (D) Immunocyto-
chemistry quantification of relative nuclear to cytoplasmic p-c-jun intensity, data represent three independent experiments, in which 20 cells were quantified from
each condition. Data were analyzed with one-way ANOVA, and Fisher test (* p < 0.05, ** p < 0.01,compared with DMSO control, n = 3).
study, increased intracellular oxidative stress in HLMVECs and
16HBEs was demonstrated in response to CFTR inhibition. Chen
et al. (2008) previously reported an increase in intracellular
H2O2 following 72 h of CFTR inhibition in human bronchial
epithelial cells. The difference lies in the rapid response in
HLMVECs, in which intracellular ROS were significantly induced
over 5–30 min following CFTR inhibition with GlyH-101 and
was reflected in a significant increase in intracellular H2O2
concentrations at 30 min compared to baseline levels. H2O2 is
a highly diffusible cell signaling molecule with multiple redox-
sensitive molecular targets. These include oxidative inactivation
of protein phosphatases and direct or indirect activation
of kinases, converging in the regulation of transcription
factor activity and effects on endothelial cell function via
increased expression of growth factors including VEGF and
transactivation of growth factor receptors including EGFR
(Bretón-Romero and Lamas, 2014; Kim and Byzova, 2014;
Marinho et al., 2014).
The ROS signal following CFTR inhibition was completely
ablated in the presence of NAC, despite the fact that NAC
has only weak direct antioxidant properties toward superoxide
anions and H2O2 (Aldini et al., 2018). However, as a precursor
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FIGURE 11 | Schematic of the impact of CFTR dysfunction in HLMVEC on
oxidative stress, inflammation and angiogenesis. Specific pharmacological
inhibition of endothelial CFTR activity is associated with an increase in
intracellular ROS (5 min) and hydrogen peroxide (30 min), an increase in
phosphorylation of c-jun and activation of AP-1 (30 min) leading to
transcription of IL-8 (16–24 h). These responses are inhibited by the
antioxidant NAC and the EGFR inhibitor AG1478, indicating a role for
EGFR-mediated ROS/H2O2 generation in the induction of IL-8 synthesis. The
increase in ROS/H2O2 is associated with increased VEGF and SOD2
expression which serve to sustain high levels of intracellular hydrogen
peroxide, via effects on VEGFR and superoxide dismutation, respectively.
Under these conditions Nrf2, the master regulator of oxidative stress, is
significantly depleted, which is proposed to occur via prolonged exposure to
high levels of H2O2, activation of GSK-3β and labeling of Nrf2 for β-TrCP
recognition, ubiquitination and degradation. The suppression of Nrf2 levels to
below normal will further sensitize endothelial cells to oxidative stress by
reducing expression of antioxidant genes. Dotted lines indicate proposed
pathways. T indicates inhibition of a pathway.
of cysteine and thus of glutathione (GSH) synthesis, NAC is
effectively an indirect antioxidant, GSH being a direct antioxidant
and a substrate of several antioxidant enzymes (Aldini et al.,
2018). CFTR may be a major transporter of GSH in both
epithelial and endothelial cells (Roum et al., 1993; Gao et al.,
1999). Impaired CFTR activity diminishes both intracellular and
extracellular GSH levels in bronchial epithelial cells (de Bari et al.,
2018), and impaired endothelial CFTR activity may contribute
to the systemic deficiency in GSH in CF (Roum et al., 1993).
A rapid, within 10 min, significant 50% decrease in GSH in
airway epithelial cells following CFTR inhibition with the CFTR
inhibitor CFTRinh-172 was recently reported (de Bari et al.,
2018). Thus, if CFTR inhibition similarly lowers intracellular
GSH concentrations in HLMVECs, this may contribute to the
observed rapid increase in ROS/H2O2 following treatment with
GlyH-101. On the other hand, the significant decrease in ROS
observed in the presence of 10 mM NAC may reflect an
increase in intracellular GSH, as previously reported for human
pulmonary vascular endothelial cells treated with 10 mM NAC
(Hashimoto et al., 2001).
Major sources of ROS production in vascular endothelial
cells include the mitochondria, endoplasmic reticulum, plasma
membrane and cytosolic enzymes (Bretón-Romero and Lamas,
2014). Mitochondrial defects and increased production of ROS,
although controversial (Schwarzer et al., 2007), have been
reported in CF lung (Valdivieso and Santa-Coloma, 2013; Atlante
et al., 2016), and gut (Kleme et al., 2018) epithelial cells.
However, the mitochondrially targeting antioxidant MitoQ did
not attenuate ROS production in HLMVEC or 16HBEs, and
since the NOX/Duox inhibitor, diphenyleneiodonium (DPI)
at 10 µM, failed to inhibit H2O2 formation, another source
of endothelial ROS is indicated (Cai, 2005), which warrants
further investigation.
Cystic fibrosis transmembrane conductance regulator
dysfunction in airway epithelial cells was previously reported to
significantly increase SOD-2, while reducing catalase, expression
(Chen et al., 2008). Similarly, inhibition of endothelial CFTR
induced a significant increase in SOD-2, albeit in the absence of
a significant decrease in catalase expression.
SOD-2 is localized in the mitochondrial matrix and catalyzes
the dismutation of O2·− to H2O2. The observed increase in SOD-
2 expression 16–24 h following CFTR inhibition, in the absence
of any increase in catalase expression, would serve to maintain
relatively high intracellular H2O2 levels in our endothelial cell
cultures, as previously reported in airway epithelial cells over
72 h (Chen et al., 2008). SOD-2 expression is not reported
to be regulated by Nrf2 (Türei et al., 2013) and, considering
the loss of Nrf2 function over 16–24 h (Figure 5), we propose
that SOD-2 expression is upregulated in response to H2O2 -
mediated activation of other redox sensitive transcription factors
(Yoshioka et al., 1994).
CFTR and Nrf2 Expression
Previous work has demonstrated, in intestinal epithelial cells, that
CFTR knockout significantly increased mitochondrial levels of
H2O2 and decreased mitochondrial levels of Nrf2 (Kleme et al.,
2018). As in bronchial epithelial cells (Chen et al., 2008), CFTR
inhibition in HLMVECs led to a 70% decrease in endothelial
Nrf2 expression in the present study, although further work is
needed to demonstrate the subcellular organelle distribution of
Nrf2 in HLMVECs.
Since Nrf2 is a transcription factor and a master regulator
of the adaptive cellular response to oxidative stress in
endothelial cells, one would expect that oxidative stress would
induce an adaptive response (reviewed in 53). Adaptive
responses are characterized by increased Nrf2 expression and
activity, upregulated antioxidant response element (ARE)-
regulated gene expression with co-ordinated induction of
endogenous cytoprotective enzymes. In view of our evidence of
oxidative stress in endothelial cells following CFTR inhibition
(increased ROS/H2O2), the observed decrease in Nrf2 is
a paradox, but one which was also previously reported
in airway epithelial cells (Chen et al., 2008). H2O2 is
further metabolized by catalase in the peroxisomes or by
the glutathione peroxidase, peroxiredoxin/thioredoxin system,
isoforms of which are found in the mitochondria and the
cytosol, and whose expression is normally regulated by
Nrf2. However, expression of these cytoprotective proteins
is decreased in CF epithelial cells, and CF nasal and lung
tissue, and this was linked to the decreased expression of Nrf2
(Chen et al., 2008).
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Nuclear related factor 2 is normally maintained at low
levels intracellularly by its association with Kelch-like ECH-
associated protein 1 (Keap-1), a substrate adapter in an E3
ubiquitin ligase complex, leading to Nrf2 ubiquitination and
proteosomal degradation (Rada et al., 2011; Marinho et al.,
2014). H2O2 oxidizes critical cysteine residues in Keap-1,
inducing conformational changes affecting the interaction
between Keap-1 and Nrf2, thereby inhibiting Nrf2 ubiquitination
and degradation. In this way, stabilization of Nrf2 by H2O2
leads to translocation and accumulation of Nrf2 in the nucleus,
upregulation of ARE-driven gene expression and coordinated
induction of endogenous cytoprotective proteins. However, Nrf2
can also be tagged for degradation by phosphorylation mediated
by glycogen synthase kinase-3β (GSK-3β). Phosphorylated
Nrf2 is recognized and bound by the β-transducin repeat
containing protein (β-TrCP), a substrate adapter forming
an E3 ligase complex, followed by ubiquitination and
proteosomal degradation of Nrf2. Since GSK-3β is inhibited
by PKB/Akt-mediated phosphorylation, and H2O2 is an
activator of the PI3K/Akt pathway, then H2O2 can also activate
Nrf2 in a Keap-1 independent manner (Rada et al., 2011;
Marinho et al., 2014).
However, while short-term exposure to H2O2 inhibits GSK-
3β and activates Nrf2, prolonged exposure to high H2O2
concentrations activates GSK-3β, which could terminate the Nrf2
signal by degradation of Nrf2 through the β-TrCP pathway
leading to lower than normal levels of Nrf2 (Rada et al., 2011;
Marinho et al., 2014). These pathways are outlined in Figure 11.
Thus it would be of future interest to investigate if antioxidants,
such as NAC, could prevent the loss of Nrf2 following CFTR
inhibition in endothelial cell cultures.
Nrf2 as a Therapeutic Target
Since, Nrf2 expression is central to limiting oxidative stress and
inflammation, the reduced expression of Nrf2 in CF airway
epithelium (Chen et al., 2008), and now also demonstrated in
pulmonary endothelial cells with dysfunctional CFTR, strongly
indicate Nrf2 may be a therapeutic target to limit oxidative
stress and airway inflammation by increasing its expression and
activation in CF. Such an approach has been demonstrated using
the synthetic triterpenoid CDDO (2-cyano-3,12-dioxooleana-1,9
(Peters et al., 2015)-dien-28-oic acid) in airway epithelial cell and
animal models of CF (Nichols et al., 2009). Further, since CDDO
activates PI3K-PKB/Akt signaling (reviewed in 53), the increase
in Nrf2 activity in CF airway epithelial cells following treatment
with CDDO (Nichols et al., 2009), suggests the reduced Nrf2
activity in preclinical models of CF lung disease is associated
with GSK-3β activity. It would therefore be of future interest
to investigate the effect of specific pharmacological activators
of PI3K-PKB/Akt and inhibitors of GSK-3β activity on Nrf2
activity in pulmonary endothelial cells. Other Nrf2 activators
include natural products such as curcumin (Balogun et al., 2003)
and sulforaphane, an isothiocyanate enriched in broccoli sprouts,
which has been proposed as a dietary supplement to activate Nrf2
(Galli et al., 2012).
In addition to regulation by proteosomal degradation,
cytosolic Nrf2 levels are regulated at the stage of Nrf2 gene
transcription. Amongst factors that increase Nrf2 transcripts
is Nrf2 itself (Suzuki et al., 2013), possibly contributing to
the overall significant decrease in Nrf2 levels following CFTR
inhibition. Of interest, is the recent observation that clinically
approved CFTR modulators rescue Nrf2 dysfunction in CF
airway epithelial cells (Borcherding et al., 2019). The effect of
CFTR modulators on endothelial Nrf-2 expression and activity
remains to be investigated.
CFTR and VEGF Expression
Increased VEGF expression and peribronchial angiogenesis is
a feature of the CF airway. VEGF promotes angiogenesis and
increased vascular permeability, enhancing inflammatory cell
recruitment and plasma exudation in the airway. Inhibition
of airway epithelial CFTR increased VEGF expression, an
effect that was dependent on EGFR activity and inhibited
by the receptor tyrosine kinase inhibitor AG1478 (Martin
et al., 2013). Further, CF airway epithelial cells have increased
EGFR activity and phosphorylation compared to normal cells
(Stolarczyk et al., 2018). Thus it was suggested that EGFR
tyrosine kinase inhibitors, such as AG1478, might be useful
in the treatment of CF. However, the findings in the present
study clearly indicate that such an approach further enhances the
increased VEGF expression observed following CFTR inhibition
in HLMVECs, and in this respect these endothelial cells differ
from epithelial cells.
Conversely, EGFR inhibition reduced IL-8 expression in
CFTR-inhibited epithelial cells (Kim et al., 2013) and, as
demonstrated in the present study, also in HLMVECs. Since anti-
inflammatory therapies targeting inhibition of EGFR are likely to
increase VEGF expression in endothelial cells, other approaches
such as those that target oxidative stress (Kim and Byzova,
2014) are needed. This notion is supported by our evidence that
the antioxidant NAC significantly reduced ROS, and both IL-8
and VEGF expression in HLMVECs. In addition, others have
recently demonstrated that ingestion of an antioxidant cocktail
can improve vascular endothelial cell function and oxidative
stress in patients with CF (Tucker et al., 2019).
CFTR and IL-8 Expression
Dysfunctional CFTR significantly increased endothelial IL-8
expression both in the absence and presence of TNFα, a pro-
inflammatory cytokine that enhances neutrophil responses in
CF airways (Nichols and Chmiel, 2015). Increased expression
of IL-8 in pulmonary epithelial cells with dysfunctional CFTR
was previously associated with increased activation of the
transcription factor NF−κB (Vij et al., 2009), which works
with other transcription factors, including AP−1, as a central
transcriptional regulator of airway inflammation in CF (Nichols
and Chmiel, 2015). Diminished Nrf2 levels are proposed to
exacerbate activation of redox sensitive pathways including
activation of AP-1 and NF-κB signaling leading to increased
IL-8 expression (Hoffmann et al., 2002) and activation of
EGFR signaling pathways (Burgel and Nadel, 2008). GlyH-101
induced a rapid (within 30 min) significant increase in the
cellular abundance of phospho-c-Jun, including an increase in
the concentration of nuclear phospho-c-Jun. These changes are
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indicative of increased c-Jun expression and activation of AP-1
signaling, which contribute to a self-amplifying cycle of increased
c-Jun abundance (Marinho et al., 2014). However, no nuclear
translocation of p65, an indicator of NF-κB activation, was seen
following treatment of HLMVECs with GlyH-101 alone for up
to 1 h, ruling out a role for NF-κB activation via the canonical
pathway in the IL-8 response to inhibition of CFTR activity.
Similarly, the CFTR inhibitor CFTRinh172 also did not induce
NF-κB activation and nuclear translocation in airway epithelial
cells (Perez et al., 2007).
Unlike GlyH-101, TNFα induced activation of both NF-
κB and AP-1 signaling, leading to significantly increased IL-8
expression in HLMVECs, beyond the response to GlyH-101
alone. Of particular interest in this respect is the recent report
that JNK is activated in CF epithelial cells and further activated in
response to TNFα (Saadane et al., 2011).
The complete inhibitory effect of AG1478 on the GlyH101-
induced increase in IL8 synthesis indicates that this response
occurred via a signaling cascade leading to ligand-dependent
EGFR signaling, as previously described for human airway
epithelial cells exposed to the CFTRinh172 (Kim et al., 2013).
EGFR activation leads to rapid (within 5 min) generation
of H2O2 (Bae et al., 1997) by mechanisms which are not
yet described (Weng et al., 2018), with immediate response
gene expression, including JUN and FOS, occurring over the
first 45 min (Avraham and Yarden, 2011). Our data therefore
indicate the early, 30 min, increase in phospho-c-Jun observed
in response to GlyH-101 is mediated via H2O2-activated EGFR
signaling (Weng et al., 2018) and involved in AP-1-mediated
IL-8 expression.
The inhibitory effect of NAC on IL-8 production in response
to GlyH-101 in the presence of TNFα further indicates that ROS
are involved in signaling pathways leading to IL-8 synthesis in
endothelial cells. Following CFTR inhibition, GlyH-101 appears
to act solely through the EGFR cascade and AP-1 activation,
while TNF-α activates both NF-κB and AP-1 signaling pathways.
ROS contribute to EGFR activation, and activation of NF-κB
and AP-1 signaling pathways, as described above. Whether
endothelial oxidative stress further contributes to increased IL-
8 gene expression through remodeling of chromatin structure
and increased histone H4 acetylation at the IL-8 promoter, as
seen in CF airway epithelial cell models (Bartling and Drumm,
2009), is not known.
GlyH-101 Is a Specific Inhibitor of
Endothelial CFTR
Some degree of non-specificity for GlyH-101 has been reported
in murine epithelial cell lines (Melis et al., 2014), although
these effects appear to be species specific (Stahl et al., 2012).
In murine cells, GlyH-101 inhibited the volume-sensitive
outwardly rectifying Cl− conductance (VSORC) and the calcium
dependent Cl− conductance (CaCC), which in endothelial cells
is predominantly TMEM16A. However, although TMEM16A
activity was reported to negatively regulate pro-inflammatory
cytokine, including IL-8, synthesis in human CF bronchial
epithelia (Veit et al., 2012), TMEM16A is a positive regulator
of endothelial ROS (Ma et al., 2017), and its inhibition would
lead to decreased ROS in endothelial cells, and not the increase
reported in the current study, supporting the involvement of
CFTR in the observed responses to GlyH-101. In our control
experiments, specific inhibition of other chloride ion channels,
VRAC and TMEM16A had no effect on IL-8 expression, and
GlyH-101 had no effect on IL-8 expression in HEK-293 cells that
do not express CFTR. Together these experiments indicate that
the observed effects of GlyH-101 in HLMVECs reflect inhibition
of CFTR activity without off-target effects.
Others reported non-specific effects of GlyH-101 on
mitochondrial respiration and a rapid increase in ROS levels
that were independent of CFTR channel inhibition, although
these were largely abrogated in the presence of 10% serum,
and under these conditions GlyH-101 had no effect on basal
oxygen consumption (Kelly et al., 2010). Serum (5%) was present
in our HLMVEC cultures to provide a reducing extracellular
environment (Chan et al., 2001) and as a source of albumin to
increase intracellular glutathione that protects pulmonary cells
from oxidant-mediated cytotoxicity (Cantin et al., 2000). Under
these conditions, but not in the absence of serum, NAC acts as an
anti-oxidant (Chan et al., 2001), as we observed. Further, we saw
no effect of MitoQ on the GlyH-101 stimulated ROS production
in HLMVECs or 16HBEs, ruling out a direct effect of GlyH-101
on mitochondrial ROS.
Therapeutic Relevance
Systemic inflammation and oxidative stress are characteristics of
people with CF and it is proposed that dysfunctional endothelial
cells contribute to these changes in the circulation in people with
CF (Declercq et al., 2019; Causer et al., 2020). Further, systemic
inflammation, oxidative stress and endothelial dysfunction were
proposed to be major risk factors for cardiovascular disease in the
aging CF population (Reverri et al., 2014). Our data now point to
a role for dysfunctional endothelial CFTR in systemic oxidative
stress and inflammation in CF.
However, to date, there are limited options for anti-
inflammatory therapy for CF (Cantin et al., 2015). Targeting
endothelial CFTR for correction and/or potentiation would seem
to be a logical therapeutic approach, as small molecule correctors
and potentiators are already in development to restore epithelial
CFTR function. It was surprising that 6 months treatment with
ivacaftor in CF patients with the G551D mutation improved lung
function, and reduced sweat chloride, indicating an effect on
CFTR function, without an effect on pulmonary inflammation
(Rowe et al., 2014). Systemic inflammation was not measured
in the study, so it is not possible to appreciate the effect of the
oral drug, ivacaftor, on endothelial function. The combination
of lumacaftor with ivacaftor (Orkambi) for delF508 patients was
approved in 2015, but to our knowledge no studies have reported
effects on systemic inflammation.
Correction of CFTR expression in the bronchial epithelium by
gene transfer in 10–25% of cells in a population was sufficient
to restore normal chloride conductance and epithelial function
(Johnson et al., 1992; Zhang et al., 2009). However, it is currently
unclear whether low-level expression in many cells (e.g., 10% of
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residual CFTR expression) or a low number of cells expressing
high levels of CFTR are required to restore normal function and
achieve clinical benefit after gene therapy (Griesenbach et al.,
2015). Recent revised estimates of the number of endothelial cells
in the human body indicate a total of 6× 1011 cells (Sender et al.,
2016), and low level of expression of CFTR in all of them may
be sufficient to maintain normal barrier, anti-inflammatory and
anti-oxidant endothelial function.
In addition to inherited defects in CFTR in people with
CF, inhibition of CFTR on endothelial cells increased the loss
of barrier function induced by exposure of endothelial cells
to cigarette smoke (Brown et al., 2014). Raju et al. (2013)
showed that smoking causes systemic CFTR dysfunction and
that acrolein present in cigarette smoke mediates CFTR defects
in extrapulmonary tissues in smokers. Endothelial dysfunction
is associated with loss of lung function, severity of disease and
reduced exercise capacity in COPD (Green and Turner, 2017).
Together, these findings indicate that acquired loss of endothelial
CFTR function in response to cigarette smoking may be relevant
to the development of vascular disease and other co-morbidities
in COPD, and a further target for therapy.
Limitations
While our data identify CFTR expressed in human lung
microvascular endothelium as a controller of oxidative stress,
ROS-mediated cell signaling and inflammatory responses, it was
based on a limited number (n = 3–6) of independent experiments.
In addition, this study was performed in a model in which normal
endothelial CFTR function was inhibited pharmacologically. To
better understand the role of dysfunctional endothelial CFTR
in people with CF, studies could be conducted using primary
endothelial cells or cell lines from people with CF in cell
culture models under shear flow, for example, and eventually in
the in vivo situation, given the importance of various cellular
interactions in inflammatory responses.
CONCLUSION
In conclusion, our study points to restoring endothelial CFTR
and Nrf2 activity as therapeutic targets in people with CF, and
supports the use of systemic antioxidants to reduce vascular
inflammation and angiogenesis in CF.
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